Abstract: The present invention relates to the use of liver-selective glucokinase activators and a GLP1 analog in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.

Abstract: The present invention relates to the use of liver-selective glucokinase activators and a GLP1 analog in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.

Abstract: The present invention relates to the use of liver-selective glucokinase activators and a GLP1 analog in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.

Abstract: The present invention relates to the use of liver-selective glucokinase activators and a GLP1 analog in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.

Abstract: The present invention relates to pharmaceutical compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid (FRI-1) in combination with an anti-diabetic drug selected from the group consisting of metformin, sitagliptin or exenatide. The present invention also relates to the use of the pharmaceutical compositions in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.

Abstract: A process for the manufacture of a layered confectionery product having discrete jelly and fat-containing confectionery components, comprising introducing a first of the components to a support, in molten or substantially-molten form, applying the second component, in non-solid form, to an exposed and non-solidified surface of the first, and allowing or effecting cooling of the first and second components such that they bond to each other as discrete confectionery layers.

Abstract: The present invention relates to pharmaceutical compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid (FRI-1) in combination with an anti-diabetic drug selected from the group consisting of metformin, sitagliptin or exenatide. The present invention also relates to the use of the pharmaceutical compositions in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.

Abstract: An information processing system for protecting against denial of service attacks comprises an interface (310) to receive and send packets, wherein the packets comprise at least one synchronization packet that is part of a handshake process for establishing the connection between the source client computer (118) and the target server computer (102); a crypto engine (306) adapted to create a unique sequence number for inclusion in a packet to be sent to a client (118) requesting establishment of a connection between a client (118) and server (102), wherein the crypto engine (306) is further adapted to validate unique sequence numbers in received synchronization packets that are part of a handshake process for establishing the connection between the source client (118) and the protected server (102); and a lookup table (304) for storing information defining established connections between the server (102) and clients so that arriving packets that purport to be part of an established connection can be validated

Abstract: The present invention relates to methods of inhibiting or reducing voluntary alcohol consumption in a subject comprising administering a non-peptidyl melanocortin 4 receptor agonist to said subject. The present invention further relates to methods of treating or preventing alcoholism, alcohol abuse, and alcohol related disorders in a subject comprising administering a non-peptidyl melanocortin 4 receptor agonist to said subject. The present invention further provides for pharmaceutical compositions and medicaments useful in carrying out these methods.

Abstract: The present invention provides a decorative light string that comprises one or more branch circuits, each of said more branch circuits is parallelly connected each other, and then connected to a common power supply wire for importing operational voltage; each said branch circuit comprises a plurality of light groups, and said plurality of light groups are serially connected in turn; each of said plurality of light groups comprises a first LED, and further comprises a protective diode parallelly connected with said first LED in a reverse direction. Said protective diode may be a rectifier diode, a zener diode, a switching diode or a second LED. In the present invention, the protective diode is parallelly connected with the first LED in the reverse direction via a welding manner and shares a pair of pins with the first LED. Further, the chip of the protective diode and the chip of the first LED may be installed into one housing to form an integrative component, thus the connecting wires are saved.

Abstract: The present invention relates to methods of treating and preventing substance addiction and substance abuse, including nicotine addiction and nicotine addiction-related disorders in a subject comprising administering a melanocortin 4 receptor agonist to said subject. The present invention further relates to methods of treating or preventing substance addiction and substance addiction-related disorders in a subject comprising administering a melanocortin 4 receptor agonist to said subject. The present invention further provides for pharmaceutical compositions and medicaments useful in carrying out these methods.

Abstract: The present invention provides a LED decorative light string that comprises one or more branch circuits, each of said more branch circuits is connected in parallel with each other, and then connected to a common power supply wire for importing operational voltage; each said branch circuit comprises a quantity of light groups, and said quantity of light groups are serially connected in turn; each said light group comprises two or more LEDs, wherein at least one LED is connected in parallel with other LEDs in reverse direction, said other LEDs are connected in parallel in the same direction. The LED decorative light string of the present invention has the advantage of more economical, more reliable in performance, longer life span.

Abstract: The present invention relates to compositions comprising an anti-obesity agent and an anti-diabetic agent useful for the treatment of diabetes, diabetes associated with obesity and diabetes-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.

Abstract: Apparatus and techniques for providing a user interface for a computing device such as a pervasive computing device. The computing device projects a user input display from a projector onto a surface. A user output display is projected from the projector of the computing device onto a surface. The user input display and the user output display may be projected from the same projector. The user input display and user output display may be projected on different surfaces. A single projected image may be split and directed with a mirror system.

Abstract: The present invention provides a LED decorative light string that comprises one or more branch circuits, each of said more branch circuits is connected in parallel with each other, and then connected to a common power supply wire for importing operational voltage; each said branch circuit comprises a quantity of light groups, and said quantity of light groups are serially connected in turn; each said light group comprises two or more LEDs, wherein at least one LED is connected in parallel with other LEDs in reverse direction, said other LEDs are connected in parallel in the same direction. The LED decorative light string of the present invention has the advantage of more economical, more reliable in performance, longer life span.

Abstract: The present invention relates to compositions comprising an anti-obesity agent and an anti-hypertensive agent useful for the treatment of hypertension, hypertension associated with obesity, and hypertension-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.

Abstract: A rat bombesin receptor subtype-3 has been isolated, cloned and sequenced. This receptor is characteristic of the G-protein family of receptors. Isolation of rat bombesin receptor subtype-3 may be used to screen and identify novel bombesin receptor modulators that may contribute to the regulation of endocrine processes, metabolism, or the cell cycle. Such compounds may be used in the treatment of conditions that result from deregulated expression of bombesin receptor subtype-3.

Abstract: The present invention relates to a biomarker for the efficacy of appetite suppressant drugs given to humans or other mammals for the treatment of obesity. It further relates to a novel method of determining the efficacy of a test compound given to a subject for the treatment of obesity, wherein the test compound is an appetite suppressant which does not stimulate the release of serotonin. It also relates to a method for following the progress of a therapeutic regime designed to alleviate obesity and to a method for determining the appropriate dosage of an appetite suppressant given to a subject for the treatment of obesity.

Abstract: The present invention relates to a method of treating or preventing obesity (or suppressing the appetite) in a human patient by antagonizing CB1 receptors and inhibiting the enzyme 11?-HSD1 in an amount that is effective to treat or prevent obesity. Compounds useful in the present invention have an ion channel activity level greater than about 2 ?M.

Abstract: The present invention features MCH-1R antagonist binding proteins. MCH-1R antagonist binding proteins described herein are based on an MCH-1R having one or more alterations to the second intracellular loop or carboxy terminus that render the receptor substantially inactive to MCH binding. An MCH-1R antagonist binding protein can bind MCH-1R antagonists, but does not exhibit high affinity MCH binding and is not activated by the MCH.